ASSOCIATION BETWEEN XRCC1 ARG399GLN AND P53 ARG72PRO POLYMORPHIC MARKERS AND THE RISK OF BREAST CANCER RISK IN KYRGYZ WOMEN

DOI: https://doi.org/None

Zh.T. Isakova (1), E.T. Talaibekova (2), K.B. Makieva (2), D.A. Asambaeva (1), B.B. Sultangazieva (2), A.A. Aldashev (1) 1 -Institute of Molecular Biology and Medicine, Togolok Moldo, 3, Bishkek, 720040, Kyrgyz Republic; 2 -National Center of Oncology, Bishkek, 720000, Ahunbaeva, 92 Kyrgyz Republic

Aim. To investigate the possible association between XRCC1 Arg399Gln and p53 Arg72Pro polymorphism and the risk of breast cancer (BC) risk in Kyrgyz women. Methods. The XRCC1 Arg399Gln and p53 Arg72Pro genotypes were determined with the use of the polymerase chain reaction-restriction fragment length polymorphism in 117 breast cancer cases and 102 controls. Results. The 399Gln allele and heterozygous genotype Arg399Gln in breast cancer patients were significantly higher than in the controls (p
Keywords: 
breast cancer, XRCC1 gene, p53 gene, polymorphism, Kyrgyz population
Список литературы: 
  1. Makieva K. Pokazateli zabolevaemosti zlokachestvennymi novoobrazovaniyami molochnoy zhelezy. Vestnik KRSU. 2014; 14 (10): 146–7. [Makieva K. Pokazateli zabolevaemosti zlokachestvennymi novoobrazovanijami molochnoj zhelezy. Vestnik KRSU. 2014; 14 (10): 146–47 (in Russian)]
  2. Duell E.J., Millikan R.C., Pittman G.S., Winkel S., Lunn R.M., Tse C.K., Eaton A., Mohrenweiser H.W. Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epimediol Biomark Prev. 2001; 10: 217–22.
  3. Lacroix M., Toillon R.A., Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006; 13 (2): 293–325.
  4. Caldecott K.W., Aoufouchi S., Johnson P., Shall S. XRCC1 polypeptide interacts with DNA polymerase β and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular «nick sensor» in vitro. Nucleic Acids Res. 1996; 24: 4387–97.
  5. Matlashewski G.J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L.V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol. 1987; 7: 961–3.
  6. Dumont P., Leu J.I., Della A.C., Pietra D.L., Murphy G. The codon72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003; 33: 357–65.
  7. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 1999; 19: 1092–100.
  8. Bland J.M., Altman D.G. Statistics notes. The odds ratio. British Med. J. 2000; 320: 1468.
  9. Luo H., Li Z., Qing Y., Zhang S.H., Peng Y., Li Q., Wang D. Single nucleotide polymorphisms of DNA base-excision repair genes (APE1, OGG1 and XRCC1) associated with breast cancer risk in a Chinese population. Asian Pac J. Cancer Prev. 2014; 15 (3): 1133–40.
  10. Romanowicz H., Smolarz B., Basczynsky J., Zadrożny M., Kulig A. Genetic polymorphism in DNA repair genes by base excision repair pathway (XRCC1) and homologous recombination (XRCC2 and RAD51) and the risk of breast carcinoma in the Polish population. Pol J. pathol. 2010; 4: 206–12.
  11. Bu T., Liu L., Sun Y., Zhao L., Peng Y., Zhou S., Li L., Chen S., Gao Y. XRCC1 Arg399Gln Polymorphism Confers Risk of Breast Cancer in American Population: A Meta-Analysis of 10846 Cases and 11723 Controls. PLoS ONE. 2014; 9 (1): 1–9.
  12. Ramadan R.A., Desouky L.M., Elnaggar M.A., Moaaz M., Elsherif A.M. Association of DNA repair genes XRCC1 (Arg399Gln), (Arg194Trp) and XRCC3 (Thr241Met) polymorphisms with the risk of breast cancer: a case-control study in Egypt. Genet Test Mol. Biomarkers. 2014; 18 (11): 754–60.
  13. Proestling K., Hebar A., Pruckner N., Marton E., Vinatzer U., Schreiber M. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLoS One. 2012; 7 (10): 47325.
  14. Huang X.E., Hamajima N., Katsuda N., Matsuo K., Hirose K., Mizutani M., Iwata H., Miura S., Xiang J., Tokudome S., Tajima K. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2003; 10 (4): 307–11.
  15. Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., Beckman G., Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996; 17: 1313–6.
  16. Zhang Z., Wang M., Wu D., Tong N., Tian Y. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast cancer research and treatment. 2010; 120: 509–17.
  17. Ohayon T., Gershoni-Baruch R., Papa M.Z., Distelman Menachem T., Eisenberg Barzilai S., Friedman E. The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br. J. Cancer. 2005; 92: 1144–8.
  18. He X.F., Su J., Zhang Y., Huang X., Liu Y., Ding D.P., Wang W., Arparkorn K. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast cancer research and treatment. 2011; 130: 517–29.
  19. Ma Y., Yang J., Liu Z., Zhang P., Yang Z., Wang Y., Qin H. No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a metaanalysis of 21 studies involving 24,063 subjects. Breast cancer research and treatment. 2011; 125: 201–5.